Kodiak Sciences Inc
KOD31.080USD
+3.630+13.22%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
1.65BMarket Cap
LossP/E TTM
More Details of Kodiak Sciences Inc Company
Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab tedromer, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy and wet age-related macular degeneration. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate designed to inhibit interleukin-6 (IL-6)-mediated inflammation and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.
Kodiak Sciences Inc Info
Ticker SymbolKOD
Company nameKodiak Sciences Inc
IPO dateOct 04, 2018
CEOPerlroth (Victor)
Number of employees109
Security typeOrdinary Share
Fiscal year-endOct 04
Address1250 Page Mill Rd
CityPALO ALTO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94304
Phone16502810850
Websitehttps://kodiak.com/
Ticker SymbolKOD
IPO dateOct 04, 2018
CEOPerlroth (Victor)
Company Executives of Kodiak Sciences Inc
Name
Name/Position
Position
Shareholding
Change
Mr. John A. Borgeson
Mr. John A. Borgeson
Chief Financial Officer, Executive Vice President, Secretary
Chief Financial Officer, Executive Vice President, Secretary
183.32K
+0.63%
Mr. Charles A. (Charlie) Bancroft
Mr. Charles A. (Charlie) Bancroft
Independent Director
Independent Director
25.95K
--
Mr. Robert A. Profusek, J.D.
Mr. Robert A. Profusek, J.D.
Lead Independent Director
Lead Independent Director
10.00K
--
Dr. Richard S. Levy, M.D.
Dr. Richard S. Levy, M.D.
Independent Director
Independent Director
1.00K
--
Dr. Taiyin Yang, Ph.D.
Dr. Taiyin Yang, Ph.D.
Independent Director
Independent Director
--
--
Dr. Victor Perlroth, M.D.
Dr. Victor Perlroth, M.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Dr. Felix J. Baker, Ph.D.
Dr. Felix J. Baker, Ph.D.
Independent Director
Independent Director
--
--
Dr. Bassil I. Dahiyat, Ph.D.
Dr. Bassil I. Dahiyat, Ph.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. John A. Borgeson
Mr. John A. Borgeson
Chief Financial Officer, Executive Vice President, Secretary
Chief Financial Officer, Executive Vice President, Secretary
183.32K
+0.63%
Mr. Charles A. (Charlie) Bancroft
Mr. Charles A. (Charlie) Bancroft
Independent Director
Independent Director
25.95K
--
Mr. Robert A. Profusek, J.D.
Mr. Robert A. Profusek, J.D.
Lead Independent Director
Lead Independent Director
10.00K
--
Dr. Richard S. Levy, M.D.
Dr. Richard S. Levy, M.D.
Independent Director
Independent Director
1.00K
--
Dr. Taiyin Yang, Ph.D.
Dr. Taiyin Yang, Ph.D.
Independent Director
Independent Director
--
--
Dr. Victor Perlroth, M.D.
Dr. Victor Perlroth, M.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Baker Bros. Advisors LP
32.66%
Point72 Asset Management, L.P.
4.65%
Perlroth (Victor D)
4.42%
BlackRock Institutional Trust Company, N.A.
3.93%
The Vanguard Group, Inc.
3.20%
Other
51.15%
Shareholders
Shareholders
Proportion
Baker Bros. Advisors LP
32.66%
Point72 Asset Management, L.P.
4.65%
Perlroth (Victor D)
4.42%
BlackRock Institutional Trust Company, N.A.
3.93%
The Vanguard Group, Inc.
3.20%
Other
51.15%
Shareholder Types
Shareholders
Proportion
Hedge Fund
46.39%
Investment Advisor
17.84%
Investment Advisor/Hedge Fund
9.17%
Individual Investor
4.78%
Research Firm
1.78%
Endowment Fund
1.13%
Private Equity
1.04%
Pension Fund
0.16%
Bank and Trust
0.07%
Other
17.64%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
248
41.93M
79.39%
-9.11M
2025Q2
273
46.04M
87.25%
-8.67M
2025Q1
302
46.32M
87.78%
-8.84M
2024Q4
308
44.88M
85.29%
-7.98M
2024Q3
318
42.74M
81.24%
-12.36M
2024Q2
326
43.49M
82.78%
-12.58M
2024Q1
345
46.64M
88.83%
-7.18M
2023Q4
377
44.39M
84.60%
-13.12M
2023Q3
391
45.97M
87.64%
-8.18M
2023Q2
401
46.07M
88.00%
-6.85M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Baker Bros. Advisors LP
17.31M
32.77%
--
--
Jun 30, 2025
Point72 Asset Management, L.P.
452.70K
0.86%
-619.72K
-57.79%
Jun 30, 2025
Perlroth (Victor D)
2.70M
5.1%
+527.00K
+24.31%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
2.69M
5.08%
-148.79K
-5.25%
Jun 30, 2025
The Vanguard Group, Inc.
1.82M
3.45%
+133.49K
+7.90%
Jun 30, 2025
Adage Capital Management, L.P.
2.06M
3.89%
+730.00K
+55.06%
Jun 30, 2025
ICONIQ Capital, LLC
1.27M
2.4%
--
--
Jun 30, 2025
TCG Crossover Management, LLC
1.15M
2.17%
--
--
Jun 30, 2025
Acadian Asset Management LLC
1.97M
3.73%
+23.74K
+1.22%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Fidelity Enhanced Small Cap ETF
0.18%
iShares Micro-Cap ETF
0.11%
Vanguard US Momentum Factor ETF
0.11%
Invesco RAFI US 1500 Small-Mid ETF
0.06%
iShares Health Innovation Active ETF
0.06%
iShares Russell 2000 Value ETF
0.05%
Invesco Russell 2000 Dynamic Multifactor ETF
0.05%
ProShares Hedge Replication ETF
0.03%
ProShares UltraPro Russell2000
0.03%
Proshares Ultra Russell 2000
0.02%
View more
Fidelity Enhanced Small Cap ETF
Proportion0.18%
iShares Micro-Cap ETF
Proportion0.11%
Vanguard US Momentum Factor ETF
Proportion0.11%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0.06%
iShares Health Innovation Active ETF
Proportion0.06%
iShares Russell 2000 Value ETF
Proportion0.05%
Invesco Russell 2000 Dynamic Multifactor ETF
Proportion0.05%
ProShares Hedge Replication ETF
Proportion0.03%
ProShares UltraPro Russell2000
Proportion0.03%
Proshares Ultra Russell 2000
Proportion0.02%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Kodiak Sciences Inc?
The top five shareholders of Kodiak Sciences Inc are:
Baker Bros. Advisors LP holds 17.31M shares, accounting for 32.77% of the total shares.
Point72 Asset Management, L.P. holds 452.70K shares, accounting for 0.86% of the total shares.
Perlroth (Victor D) holds 2.70M shares, accounting for 5.10% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 2.69M shares, accounting for 5.08% of the total shares.
The Vanguard Group, Inc. holds 1.82M shares, accounting for 3.45% of the total shares.
Baker Bros. Advisors LP holds 17.31M shares, accounting for 32.77% of the total shares.
Point72 Asset Management, L.P. holds 452.70K shares, accounting for 0.86% of the total shares.
Perlroth (Victor D) holds 2.70M shares, accounting for 5.10% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 2.69M shares, accounting for 5.08% of the total shares.
The Vanguard Group, Inc. holds 1.82M shares, accounting for 3.45% of the total shares.
What are the top three shareholder types of Kodiak Sciences Inc?
The top three shareholder types of Kodiak Sciences Inc are:
Baker Bros. Advisors LP
Point72 Asset Management, L.P.
Perlroth (Victor D)
Baker Bros. Advisors LP
Point72 Asset Management, L.P.
Perlroth (Victor D)
How many institutions hold shares of Kodiak Sciences Inc (KOD)?
As of 2025Q3, 248 institutions hold shares of Kodiak Sciences Inc, with a combined market value of approximately 41.93M, accounting for 79.39% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -7.87%.
What is the biggest source of revenue for Kodiak Sciences Inc?
In --, the -- business generated the highest revenue for Kodiak Sciences Inc, amounting to -- and accounting for --% of total revenue.
